CatalystMarker
← board

PBMWW

distress 3/10 · well-funded / low risk
$0.03-3%today-3% from 52w high
psyencebiomed.com12 employeesToronto, ON
Revenue
pre-revenue
Liquidity
$16M
Runway
1.9 yrs
Shares 1y
0%

Price & events

+52.5% over 6M
$0.02$0.02$0.03Mar 26May 26Jul 2687k
CatalystRating changeDilutionFinancingdashed = today
-2.6%
1D
+26.0%
1W
+52.5%
1M
+52.5%
3M
—
6M
—
1Y
—
2Y
—
5Y
+52.5%
All

Overview

Market Cap
$69.94K
Volume
181
52 Week Range
$0.02 – $0.03
Total Shares
2.29M
Float Shares
2.61M
RVOL
0.06x
Beta
1.68

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 2,293,277 · 3 offerings/1y · 0 PIPEs
  • 2025-11-20424B3offering
  • 2025-11-12424B3offering
  • 2025-11-03424B3offering
  • 2025-10-14F-1/Ashelf_registration
  • 2025-10-06F-1/Ashelf_registration
  • 2025-08-06F-3shelf_registration
  • 2025-03-14EFFECTshelf_effective
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.